Janux Therapeutics
JANX
160 hedge funds and large institutions have $2.07B invested in Janux Therapeutics in 2024 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 56 increasing their positions, 49 reducing their positions, and 27 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
19% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 27
14% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 49
11% more capital invested
Capital invested by funds: $1.87B → $2.07B (+$199M)
3% more funds holding
Funds holding: 155 → 160 (+5)
1.21% more ownership
Funds ownership: 86.26% → 87.46% (+1.2%)
86% less call options, than puts
Call options by funds: $4.14M | Put options by funds: $29.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$56.5M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$36.4M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$31.4M |
| 4 |
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Warszawa,
Poland
|
+$20.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$74.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$23.8M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$18.5M |
| 4 |
SC
Samlyn Capital
New York
|
-$13.6M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$12.1M |
JANX Hedge Fund Activity: Q3 2024 in Review
160 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q3 2024, worth a combined $2.07B — up 11% from $1.87B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new JANX positions and 27 closed out — a net gain of 5 holders — while 56 added to existing stakes and 49 trimmed.
The largest buyer was Woodline Partners, adding an estimated $56.5M. The largest seller was OrbiMed, cutting an estimated $74.9M.
- 160 institutional investors held Janux Therapeutics (JANX) as of Q3 2024, up from 155 in Q2 2024.
- Funds reported $2.07B of Janux Therapeutics stock for Q3 2024, up 11% quarter-over-quarter.
- 32 funds opened new Janux Therapeutics positions in Q3 2024 and 27 closed out, a net change of +5 holders.
- The largest Janux Therapeutics buyer in Q3 2024 was Woodline Partners, an estimated $56.5M added.
- The largest Janux Therapeutics seller in Q3 2024 was OrbiMed, an estimated $74.9M sold.
Based on aggregated 13F filings for Q3 2024.